SRR650133
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.530
- G2M_CHECKPOINT+0.430
- INTERFERON_ALPHA_RESPONSE+0.340
- SPERMATOGENESIS+0.330
- MITOTIC_SPINDLE+0.320
- PROTEIN_SECRETION+0.210
- INTERFERON_GAMMA_RESPONSE+0.180
- ESTROGEN_RESPONSE_EARLY+0.170
- ESTROGEN_RESPONSE_LATE+0.140
- KRAS_SIGNALING_DN+0.120
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.620
- MYC_TARGETS_V2-0.440
- HYPOXIA-0.410
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.390
- ADIPOGENESIS-0.380
- P53_PATHWAY-0.370
- COAGULATION-0.350
- MYC_TARGETS_V1-0.320
- WNT_BETA_CATENIN_SIGNALING-0.320
- UNFOLDED_PROTEIN_RESPONSE-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CR-7368-01A-11R-2132-07 | — | — | 0.793 |
| 2 | SRR650131 | — | — | 0.781 |
| 3 | TCGA-A2-A25C-01A-11R-A169-07 | — | B | 0.761 |
| 4 | 5b217223-8b43-47b6-a694-c808b643c3c3 | — | — | 0.750 |
| 5 | TCGA-A7-A2KD-01A-31R-A21T-07 | — | C | 0.739 |
| 6 | SRR6079981 | — | — | 0.735 |
| 7 | 29c49da8-3d12-425d-abe6-de2be5e6807f | — | — | 0.727 |
| 8 | R218 | — | — | 0.711 |
| 9 | MNG34 | — | — | 0.708 |
| 10 | SRR2932842 | — | — | 0.705 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.530 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.430 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.340 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.330 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.320 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.210 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.180 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.170 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.140 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.120 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.080 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.060 | Temsirolimus | — uncovered |
| ANDROGEN_RESPONSE | 0.050 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.040 | Inavolisib | — uncovered |